Barclays
IBER

Barclays’s Ibere Pharmaceuticals IBER Stock Holding History

Barclays’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-49,023
Closed -$486K – 5477
2022
Q3 		$486K Hold
49,023
– – ﹤0.01% 2722
2022
Q2 		$481K Buy
+49,023
New +$481K ﹤0.01% 2892

Other funds holding IBER

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Barclays's IBER Position: Q4 2022 in Review

Barclays sold out of Ibere Pharmaceuticals (IBER) in Q4 2022, closing a stake of 49,023 shares — an estimated $486K sold.

Barclays first reported a position in IBER in Q2 2022 and held it in 2 quarters. The position peaked at $486K in Q3 2022. 47 funds tracked by Wall St. Rank hold IBER as of Q4 2022.

  • Barclays reported no remaining Ibere Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 49,023 Ibere Pharmaceuticals shares in Q4 2022, an estimated $486K.
  • Barclays first reported a position in Ibere Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Barclays's Ibere Pharmaceuticals position peaked at $486K in Q3 2022.
  • 47 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.